Stockscreener 앱 받기
4.16
2.58%
-0.11
전일 마감가:
$4.27
열려 있는:
$4.3
하루 거래량:
129.13K
Relative Volume:
0.43
시가총액:
$12.81M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-0.272
EPS:
-15.2954
순현금흐름:
$-24.23M
1주 성능:
+4.52%
1개월 성능:
-11.30%
6개월 성능:
-74.00%
1년 성능:
-90.44%
1일 변동 폭
$4.0845
$4.30
1주일 범위
$3.864
$4.60
52주 변동 폭
$3.13
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
MBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
4.16 | 13.15M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 재개 | H.C. Wainwright | Buy |
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
New brain cancer trial tests WP1066 plus radiation in glioblastoma - Stock Titan
MBRXMoleculin Biotec Latest Stock News & Market Updates - Stock Titan
Moleculin’s Annamycin shows no cardiotoxicity in cancer trials By Investing.com - Investing.com Nigeria
Moleculin Highlights Non-Cardiotoxic Profile of Lead Annamycin Drug - TipRanks
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects - The Manila Times
Moleculin Biotech, Inc. Reports No Cardiotoxicity in Annamycin Trials - TradingView — Track All Markets
Moleculin Biotech, Inc. Reports No Evidence of Cardiotoxicity for Annamycin Across Five Clinical Trials - Quiver Quantitative
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - MSN
Moleculin expects first MIRACLE trial data readout in Q1 2026 By Investing.com - Investing.com Nigeria
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech (MBRX) Readies Annamycin for Major Milestones in 2026 - GuruFocus
Moleculin expects first MIRACLE trial data readout in Q1 2026 - Investing.com
Moleculin Biotech advances Annamycin AML Phase 3 program - TipRanks
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs - The Manila Times
Moleculin Biotech, Inc. Announces Milestones and Upcoming Unblinding for MIRACLE Trial in Acute Myeloid Leukemia and New Pancreatic Cancer Initiatives - Quiver Quantitative
Moleculin accelerates outlook into 2026 with first pivotal trial unblinding on track, global trial expansion, and multiple externally/IIT funded clinical programs - marketscreener.com
Moleculin Biotech, Inc. Accelerates 2026 Outlook with Key Clinical Trials - TradingView — Track All Markets
Experimental chemo aiming to spare the heart nears key 2026 trial test - Stock Titan
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Buy Signal: Why Moleculin Biotech Inc. stock could rally in 20252025 Stock Rankings & Weekly Chart Analysis and Trade Guides - Улправда
What technical charts say about Moleculin Biotech Inc. stockGap Up & Reliable Breakout Stock Forecasts - Улправда
Why retail investors favor Moleculin Biotech Inc. stockEarnings Miss Alerts & Free Fast Track Wealth Growth - ulpravda.ru
Moleculin Biotech, Inc.Common Stock (Nasdaq:MBRX) Stock Quote - FinancialContent
Why Moleculin Biotech Inc. stock is considered a top pickMarket Insider Reports & Budget Friendly Trading Strategies - Улправда
Moleculin Biotech regains Nasdaq listing compliance - marketscreener.com
Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements - TipRanks
Moleculin Biotech Regains Nasdaq Compliance - TradingView — Track All Markets
Why Moleculin Biotech Inc. stock remains a top recommendation2026 world cup usa national team round of 32 midfield engines counter attacking tactical prediction breakdown - Улправда
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech’s Wild Ride: Is Tiny-Cap MBRX the Next Viral Moonshot or Total Trap? - AD HOC NEWS
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Biotech enters inducement offer agreements - MSN
Moleculin Biotech begins dosing subjects in combination therapy trial for AML - MSN
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million - Investing.com Nigeria
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million By Investing.com - Investing.com South Africa
Moleculin Biotech Amends Warrants to Boost Nasdaq Compliance - TipRanks
Moleculin Biotech Signs Warrant Amendment Agreements With Holders of Series E, F and G Warrants - TradingView — Track All Markets
Moleculin Biotech amends warrants to boost Nasdaq compliance - MSN
Moleculin Biotech shares slide after release of pediatric brain tumor trial data - MSN
Will Moleculin Biotech Inc. stock rally after Fed decisions2025 Volatility Report & Long Hold Capital Preservation Tips - Улправда
Will Moleculin Biotech Inc. stock split attract more investorsMarket Performance Report & Safe Capital Growth Plans - Улправда
Moleculin Biotech Earnings Notes - Trefis
Moleculin Biotech (LTS:0K2H) EV-to-OCF : -0.07 (As of Dec. 19, 2025) - GuruFocus
How risky is Moleculin Biotech Inc. (MOL) stock compared to peersJuly 2025 Spike Watch & Target Return Focused Picks - DonanımHaber
Why Moleculin Biotech Inc. (MOL) stock is listed among top recommendationsJuly 2025 PreEarnings & Technical Pattern Based Signals - DonanımHaber
Market Review: Why Moleculin Biotech Inc. stock could rally in 2025July 2025 Snapshot & Fast Gain Swing Alerts - DonanımHaber
Why Moleculin Biotech Inc. stock could rally in 2025Global Markets & Verified Momentum Stock Watchlist - DonanımHaber
Aug Wrap: Why Moleculin Biotech Inc. stock is considered a top pickJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - Улправда
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Moleculin Biotech Inc 주식 (MBRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
4.73%
0.92%
자본화:
|
볼륨(24시간):